CINECA IRIS Institutional Research Information System

COMOGLIO, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.555
EU - Europa 14.083
AS - Asia 9.668
SA - Sud America 156
OC - Oceania 146
AF - Africa 108
Continente sconosciuto - Info sul continente non disponibili 16
Totale 45.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.923
CN - Cina 5.402
IT - Italia 2.417
DE - Germania 1.732
IE - Irlanda 1.557
SE - Svezia 1.474
GB - Regno Unito 1.402
SG - Singapore 1.399
UA - Ucraina 1.351
FR - Francia 1.308
FI - Finlandia 909
KR - Corea 905
JP - Giappone 655
CA - Canada 580
PL - Polonia 428
ES - Italia 333
IN - India 304
VN - Vietnam 190
NL - Olanda 187
AT - Austria 184
BE - Belgio 170
HK - Hong Kong 158
CH - Svizzera 153
TW - Taiwan 128
TR - Turchia 121
AU - Australia 120
BR - Brasile 108
ID - Indonesia 106
RU - Federazione Russa 90
GR - Grecia 79
IR - Iran 50
RO - Romania 50
SN - Senegal 48
TH - Thailandia 48
DK - Danimarca 44
MX - Messico 42
PT - Portogallo 42
IL - Israele 39
CZ - Repubblica Ceca 37
PK - Pakistan 29
NZ - Nuova Zelanda 26
SA - Arabia Saudita 24
HU - Ungheria 23
NO - Norvegia 21
MY - Malesia 20
EG - Egitto 18
JO - Giordania 14
AR - Argentina 13
CL - Cile 13
UZ - Uzbekistan 13
EU - Europa 12
HR - Croazia 11
CO - Colombia 10
MU - Mauritius 10
BG - Bulgaria 9
RS - Serbia 9
ZA - Sudafrica 9
EE - Estonia 8
LB - Libano 8
LT - Lituania 8
PE - Perù 8
PH - Filippine 8
SI - Slovenia 8
DZ - Algeria 7
LK - Sri Lanka 7
SK - Slovacchia (Repubblica Slovacca) 7
AM - Armenia 6
GE - Georgia 6
KE - Kenya 6
LU - Lussemburgo 6
BA - Bosnia-Erzegovina 5
IQ - Iraq 5
AE - Emirati Arabi Uniti 4
IM - Isola di Man 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
AP - ???statistics.table.value.countryCode.AP??? 3
BY - Bielorussia 3
IS - Islanda 3
MK - Macedonia 3
MO - Macao, regione amministrativa speciale della Cina 3
PR - Porto Rico 3
QA - Qatar 3
AZ - Azerbaigian 2
BO - Bolivia 2
GL - Groenlandia 2
KZ - Kazakistan 2
MA - Marocco 2
NG - Nigeria 2
TN - Tunisia 2
A1 - Anonimo 1
AL - Albania 1
BD - Bangladesh 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
GH - Ghana 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
Totale 45.724
Salva come PNG Salva come JPEG
Città #
Beijing 2.500
Chandler 2.414
Ann Arbor 1.900
Dublin 1.546
Santa Clara 1.081
Singapore 1.065
Houston 919
Fairfield 815
Jacksonville 809
Dearborn 642
Ashburn 616
Wilmington 599
Medford 559
Villeurbanne 513
Princeton 493
Shanghai 483
Woodbridge 471
Milan 439
Columbus 423
Warsaw 392
Redwood City 365
Nyköping 364
Seattle 350
Toronto 311
Torino 310
Cambridge 280
Guangzhou 237
Verona 226
Boardman 213
Tokyo 197
Boston 175
Nanjing 175
Pisa 175
Vienna 164
Fremont 159
New York 156
Falls Church 144
Turin 144
Dong Ket 131
Lachine 111
Los Angeles 110
Brussels 102
Rome 97
Hefei 92
Wuhan 90
Hangzhou 89
Jakarta 89
Zhengzhou 89
London 79
Taipei 76
Chengdu 71
Norwalk 71
San Diego 70
Munich 65
Jinan 64
Paris 61
Changsha 60
Madrid 57
Duncan 56
Buffalo 54
Shenyang 54
Helsinki 52
Kunming 52
Chicago 51
Barcelona 48
Seoul 48
Amsterdam 47
Mountain View 45
Nanchang 44
Ottawa 44
Washington 39
São Paulo 37
Shenzhen 35
Istanbul 33
Manchester 33
Pune 33
San Francisco 32
Berlin 31
Xian 31
Florence 30
Silver Spring 30
Auburn Hills 29
Dallas 29
Hebei 29
Tianjin 29
Fuzhou 28
Chongqing 27
Hong Kong 27
Düsseldorf 25
Nürnberg 25
Osaka 25
Bangkok 24
Central 24
Mumbai 24
San Jose 23
Rochester 22
Luni 21
Melbourne 21
Nashville 21
Tappahannock 21
Totale 25.931
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.194
MET signalling: principles and functions in development, organ regeneration and cancer. 1.590
Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy 1.583
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer 765
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 724
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 663
MET mutations in cancers of unknown primary origin (CUPs). 448
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 321
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 319
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 279
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor 253
Only a subset of Met-activated pathways are required to sustain oncogene addiction 250
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 242
Targeting the oncogenic Met receptor by antibodies and gene therapy. 232
Met-driven invasive growth involves transcriptional regulation of Arhgap12 230
Targeting the MET oncogene in cancer and metastases. 229
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 223
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis 219
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 219
Inhibition of Src impairs the growth of met-addicted gastric tumors. 218
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. 217
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. 213
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells 210
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. 192
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 192
Ron kinase transphosphorylation sustains MET oncogene addiction 191
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 188
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 185
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 185
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 184
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 180
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. 172
Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy 167
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 167
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody 164
THE EXPRESSION OF LINE1-MET CHIMERIC TRANSCRIPT IDENTIFIES A SUBGROUP OF AGGRESSIVE BREAST CANCERS 164
TNF-α promotes invasive growth through the MET signaling pathway. 162
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. 161
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells. 159
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 158
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 152
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. 151
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. 150
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis 149
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. 148
MET inhibition overcomes radiation resistance of glioblastoma stem-like cells 148
Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. 147
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer. 146
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. 145
Activation of RAS family members confers resistance to ROS1 targeting drugs. 144
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 144
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. 141
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 141
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. 139
A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. 139
Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. 136
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk 136
A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor 133
"Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection 132
A differentiation switch for genetically modified hepatocytes. 132
Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). 132
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer 132
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. 131
Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. 129
Biosynthesis of the protein encoded by the c-met proto-oncogene 128
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy 126
Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report 125
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. 124
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 124
"Active" cancer immunotherapy by anti-Met antibody gene transfer 123
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors 123
The MET Oncogene in Glioblastoma Stem Cells: Implications as a Diagnostic Marker and a Therapeutic Target. 122
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort 122
A point mutation in the MET oncogene abrogates metastasis without affecting transformation. 118
Multinucleated giant cells in organ cultures of spleen. 116
Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. 116
MicroRNAs impair MET-mediated invasive growth 116
Different point mutations in the met oncogene elicit distinct biological properties. 114
HGF: a multifunctional growth factor controlling cell scattering. 113
WHEN REGULATION FAILS: HOW CANCER ARISES 113
HGF receptor agonists protect cardiomyocytes from CoCl2-induced cell injury 112
A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. 111
[Molecular markers study in pTNM of squamous carcinoma of the head and neck] 110
Scatter factor receptors are key players in a unique multistep program leading to invasive growth. 109
A gene trap vector system for identifying transcriptionally responsive genes 108
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. 107
Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib 107
Biochemical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3. 106
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 106
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 106
Biochemical and immunological properties of the human carcinoma antigen CAR-5 defined by the monoclonal antibody BD-5. 105
HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death 104
A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth 104
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 104
HGF/Met tyrosine kinase receptor in heart physiology and pathophysiology 104
CONSTITUTIVE ACTIVATION OF THE RON GENE INDUCES INVASIVE GROWTH BUT NOT TRANSFORMATION 101
[The distribution of motor plates in the mimic muscles of the dog (Canis familiaris L.)] 100
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met 97
ERK: A key player in the pathophysiology of cardiac hypertrophy 97
A comparative study of SV40-transformed fibroblast plasma membrane proteins labelled by enzymatic iodination or with trinitrobenzene sulfonate. 96
Totale 25.206
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.934
article - articoli 0
book - libri 0
conference - conferenze 5.839
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.052 0 0 0 0 0 1.039 785 400 624 529 451 224
2020/20215.094 382 246 468 320 471 277 538 192 712 452 369 667
2021/20226.751 465 486 443 559 352 342 611 383 295 423 1.227 1.165
2022/20237.782 812 512 224 751 757 1.762 653 531 863 176 460 281
2023/20244.247 540 657 241 316 260 478 218 275 67 266 399 530
2024/20254.068 168 571 364 904 1.928 133 0 0 0 0 0 0
Totale 47.081